drugset
drugset / Trial / NCT04279769

Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

NCT04279769 ↗

Phase 1 Completed 32 enrolled Calithera Biosciences, Inc
RandomizedSequentialDouble-blindTreatment

Summary

This is a phase 1b multiple ascending dose escalation study to evaluate the safety and tolerability of arginase inhibitor CB-280 in subjects with cystic fibrosis.

Timeline

Start
2020-07-03
Primary completion
2021-11-23
Completion
2021-11-23

Drugs

EvaluationDrugModalityDoseRoute
Subject CB-280 Unknown 50 mg Oral
Subject CB-280 Unknown 100 mg Oral
Subject CB-280 Unknown 200 mg Oral
Subject CB-280 Unknown 400 mg Oral

Indications

cystic fibrosis